Cora N. Sternberg

TL;DR: Cabazitaxel significantly improved median radiographic progression-free survival (rPFS) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) who had previously received docetaxel and progressed ≤12 mo on the alternative agent (abiraterone/enzalutamide) as discussed by the authors.

TL;DR: Patients with advanced urothelial cancer who progress after checkpoint inhibitor (CPI) therapy (following failure of or ineligibility for platinum-based chemotherapy) are referred for follow-up treatment with a second line therapy.

TL;DR: This data indicates that certain sites of PSMA expression (e.g. salivary/lacrimal glands, kidneys, small bowel) are not affected by antibodies or small molecules targeting PSMA with different biodistribution.

TL;DR: This work presents a meta-analysis of 129 cases of central giant cell granuloma found in patients treated with a single excision technique at the London School of Hygiene and Tropical Medicine over a 12-month period in what is believed to be the first such study of its kind in the world.

TL;DR: Whereas the hypothesis that combining sunitinib and enzastaurin may result in greater antiangiogenic effects in RCC is based on solid scientific evidence, part 2 of the study was not activated due to the high number of TEAE-related dose reductions at the expected efficacious dose and overall decision by the sponsor not to pursue further development of enzasturin for solid tumors.